Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 464

1.

Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study.

Smit M, van Pelt G, Roodvoets A, Meershoek-Klein Kranenbarg E, Putter H, Tollenaar R, van Krieken JH, Mesker W.

JMIR Res Protoc. 2019 Jun 14;8(6):e13464. doi: 10.2196/13464.

2.

Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study.

Dufraing K, van Krieken JH, De Hertogh G, Hoefler G, Oniscu A, Kuhlmann TP, Weichert W, Marchiò C, Ristimäki A, Ryska A, Scoazec JY, Dequeker E.

Histopathology. 2019 May 4. doi: 10.1111/his.13891. [Epub ahead of print]

PMID:
31054167
3.

Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.

Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodríguez-Perales S, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkær K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH.

Cancer Immunol Res. 2019 Apr;7(4):644-657. doi: 10.1158/2326-6066.CIR-18-0439. Epub 2019 Feb 11.

PMID:
30745366
4.

PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.

Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Zhang M, Winter JN, Medeiros LJ, Rassidakis GZ, Vaupel CA, Li Y, Dakappagari N, Xu-Monette ZY, Young KH.

Mod Pathol. 2019 Jun;32(6):741-754. doi: 10.1038/s41379-018-0193-5. Epub 2019 Jan 21.

PMID:
30666052
5.

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Klöppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA.

Mod Pathol. 2018 Dec;31(12):1770-1786. doi: 10.1038/s41379-018-0110-y. Epub 2018 Aug 23.

6.

Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations.

van Pelt GW, Kjær-Frifeldt S, van Krieken JHJM, Al Dieri R, Morreau H, Tollenaar RAEM, Sørensen FB, Mesker WE.

Virchows Arch. 2018 Oct;473(4):405-412. doi: 10.1007/s00428-018-2408-z. Epub 2018 Jul 20.

7.

Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.

Wang X, Cao X, Sun R, Tang C, Tzankov A, Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, Tan X, Pang Y, Visco C, Xie Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Winter JN, Piris MA, Li S, Miranda RN, Medeiros LJ, Li Y, Xu-Monette ZY, Young KH.

Neoplasia. 2018 Jun;20(6):574-593. doi: 10.1016/j.neo.2018.03.002. Epub 2018 May 4.

8.

Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe.

Keppens C, Palma JF, Das PM, Scudder S, Wen W, Normanno N, van Krieken JH, Sacco A, Fenizia F, Gonzalez de Castro D, Hönigschnabl S, Kern I, Lopez-Rios F, Lozano MD, Marchetti A, Halfon P, Schuuring E, Setinek U, Sorensen B, Taniere P, Tiemann M, Vosmikova H, Dequeker EMC.

J Mol Diagn. 2018 Jul;20(4):483-494. doi: 10.1016/j.jmoldx.2018.03.006. Epub 2018 Apr 26.

PMID:
29704571
9.

External Quality Assessment Identifies Training Needs to Determine the Neoplastic Cell Content for Biomarker Testing.

Dufraing K, De Hertogh G, Tack V, Keppens C, Dequeker EMC, van Krieken JH.

J Mol Diagn. 2018 Jul;20(4):455-464. doi: 10.1016/j.jmoldx.2018.03.003. Epub 2018 Apr 3.

PMID:
29625250
10.

Confirmation of a metastasis-specific microRNA signature in primary colon cancer.

Coebergh van den Braak RRJ, Sieuwerts AM, Lalmahomed ZS, Smid M, Wilting SM, Bril SI, Xiang S, van der Vlugt-Daane M, de Weerd V, van Galen A, Biermann K, van Krieken JHJM, Kloosterman WP, Foekens JA; MATCH study group*, Martens JWM, IJzermans JNM.

Sci Rep. 2018 Mar 27;8(1):5242. doi: 10.1038/s41598-018-22532-1.

11.

The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact.

van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken JHJM, Tollenaar RAEM, Mesker WE.

Histopathology. 2018 Aug;73(2):197-206. doi: 10.1111/his.13489. Epub 2018 Mar 24. Review.

PMID:
29457843
12.

RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment.

Tack V, Ligtenberg MJL, Siebers AG, Rombout PDM, Dabir PD, Weren RDA, van Krieken JHJM, Dequeker EMC.

Virchows Arch. 2018 May;472(5):717-725. doi: 10.1007/s00428-017-2291-z. Epub 2018 Jan 15.

PMID:
29333594
13.

Role of germline aberrations affecting CTNNA1, MAP3K6 and MYD88 in gastric cancer susceptibility.

Weren RDA, van der Post RS, Vogelaar IP, van Krieken JH, Spruijt L, Lubinski J, Jakubowska A, Teodorczyk U, Aalfs CM, van Hest LP, Oliveira C, Kamping EJ, Schackert HK, Ranzani GN, Gómez García EB, Hes FJ, Holinski-Feder E, Genuardi M, Ausems MGEM, Sijmons RH, Wagner A, van der Kolk LE, Cats A, Bjørnevoll I, Hoogerbrugge N, Ligtenberg MJL.

J Med Genet. 2018 Oct;55(10):669-674. doi: 10.1136/jmedgenet-2017-104962. Epub 2018 Jan 12.

14.

New developments in the pathology of malignant lymphoma. A review of the literature published from September-August 2017.

van Krieken JH.

J Hematop. 2017 Nov 29;10(3-4):117-127. doi: 10.1007/s12308-017-0310-2. eCollection 2017 Dec. Review. No abstract available.

15.

Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma.

Schreuder MI, van den Brand M, Hebeda KM, Groenen PJTA, van Krieken JH, Scheijen B.

J Hematop. 2017 Sep 25;10(3-4):91-107. doi: 10.1007/s12308-017-0302-2. eCollection 2017 Dec. Review.

16.

New developments in the pathology of malignant lymphoma: a review of the literature published from May to August 2017.

van Krieken JH.

J Hematop. 2017 Sep 30;10(2):65-73. doi: 10.1007/s12308-017-0303-1. eCollection 2017 Jun. Review. No abstract available.

17.

High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients.

Coebergh van den Braak RRJ, Sieuwerts AM, Kandimalla R, Lalmahomed ZS, Bril SI, van Galen A, Smid M, Biermann K, van Krieken JHJM, Kloosterman WP, Foekens JA, Goel A, Martens JWM, IJzermans JNM; MATCH study group.

PLoS One. 2017 Sep 28;12(9):e0185607. doi: 10.1371/journal.pone.0185607. eCollection 2017.

18.

Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.

Visco C, Wang J, Tisi MC, Deng L, D'Amore ESG, Tzankov A, Montes-Moreno S, Dybkær K, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Medeiros LJ, Xu-Monette ZY, Young KH.

Br J Cancer. 2017 Nov 21;117(11):1685-1688. doi: 10.1038/bjc.2017.345. Epub 2017 Sep 26.

19.

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity.

Hato SV, Figdor CG, Takahashi S, Pen AE, Halilovic A, Bol KF, Vasaturo A, Inoue Y, de Haas N, Verweij D, Van Herpen CML, Kaanders JH, van Krieken JHJM, Van Laarhoven HWM, Hooijer GKJ, Punt CJA, Asai A, de Vries IJM, Lesterhuis WJ.

Oncotarget. 2017 May 7;8(33):54434-54443. doi: 10.18632/oncotarget.17661. eCollection 2017 Aug 15.

20.

Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing.

Vogelaar IP, van der Post RS, van Krieken JHJ, Spruijt L, van Zelst-Stams WA, Kets CM, Lubinski J, Jakubowska A, Teodorczyk U, Aalfs CM, van Hest LP, Pinheiro H, Oliveira C, Jhangiani SN, Muzny DM, Gibbs RA, Lupski JR, de Ligt J, Vissers LELM, Hoischen A, Gilissen C, van de Vorst M, Goeman JJ, Schackert HK, Ranzani GN, Molinaro V, Gómez García EB, Hes FJ, Holinski-Feder E, Genuardi M, Ausems MGEM, Sijmons RH, Wagner A, van der Kolk LE, Bjørnevoll I, Høberg-Vetti H, van Kessel AG, Kuiper RP, Ligtenberg MJL, Hoogerbrugge N.

Eur J Hum Genet. 2017 Nov;25(11):1246-1252. doi: 10.1038/ejhg.2017.138. Epub 2017 Sep 6.

21.

New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2017.

van Krieken JH.

J Hematop. 2017 Jul 22;10(1):25-33. doi: 10.1007/s12308-017-0295-x. eCollection 2017 Mar. Review. No abstract available.

22.

Pathways towards indolent B-cell lymphoma - Etiology and therapeutic strategies.

van den Brand M, Scheijen B, Hess CJ, van Krieken JHJ, Groenen PJTA.

Blood Rev. 2017 Nov;31(6):426-435. doi: 10.1016/j.blre.2017.08.002. Epub 2017 Aug 5. Review.

PMID:
28802906
23.

RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data.

Kafatos G, Niepel D, Lowe K, Jenkins-Anderson S, Westhead H, Garawin T, Traugottová Z, Bilalis A, Molnar E, Timar J, Toth E, Gouvas N, Papaxoinis G, Murray S, Mokhtar N, Vosmikova H, Fabian P, Skalova A, Wójcik P, Tysarowski A, Barugel M, van Krieken JH, Trojan J.

Biomark Med. 2017 Sep;11(9):751-760. doi: 10.2217/bmm-2016-0358. Epub 2017 Jul 27.

24.

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Winter JN, Piris MA, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH.

Leukemia. 2018 Feb;32(2):353-363. doi: 10.1038/leu.2017.222. Epub 2017 Jul 12.

25.

Quality in pathology.

van Krieken JHJM.

Virchows Arch. 2017 Sep;471(3):311-312. doi: 10.1007/s00428-017-2200-5. Epub 2017 Jul 18. No abstract available.

PMID:
28721489
26.

AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.

Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Dybkær K, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Wang S, Møller MB, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH.

Am J Pathol. 2017 Aug;187(8):1700-1716. doi: 10.1016/j.ajpath.2017.04.009. Epub 2017 Jun 13.

27.

Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria.

van der Post RS, van Dieren J, Grelack A, Hoogerbrugge N, van der Kolk LE, Snaebjornsson P, Lansdorp-Vogelaar I, van Krieken JH, Bisseling TM, Cats A.

Gastrointest Endosc. 2018 Feb;87(2):397-404.e2. doi: 10.1016/j.gie.2017.04.016. Epub 2017 Apr 25.

PMID:
28455161
28.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories.

Torlakovic EE, Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Vyberg M, Zhou X, Taylor CR; From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and International Quality Network for Pathology (IQN Path).

Appl Immunohistochem Mol Morphol. 2017 Mar;25(3):151-159. doi: 10.1097/PAI.0000000000000470.

PMID:
28187030
29.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics.

Torlakovic EE, Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Vyberg M, Zhou X, Taylor CR; From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and International Quality Network for Pathology (IQN Path).

Appl Immunohistochem Mol Morphol. 2017 Feb;25(2):79-85. doi: 10.1097/PAI.0000000000000444. Review.

PMID:
28182587
30.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry.

Cheung CC, D'Arrigo C, Dietel M, Francis GD, Fulton R, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Taylor CR, Vyberg M, Zhou X, Torlakovic EE; From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and International Quality Network for Pathology (IQN Path).

Appl Immunohistochem Mol Morphol. 2017 Apr;25(4):227-230. doi: 10.1097/PAI.0000000000000469.

PMID:
27941560
31.

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers.

Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Taylor CR, Vyberg M, Zhou X, Torlakovic EE; From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and International Quality Network for Pathology (IQN Path).

Appl Immunohistochem Mol Morphol. 2017 Jan;25(1):4-11.

PMID:
27922482
32.

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.

Boleij A, Tack V, Taylor A, Kafatos G, Jenkins-Anderson S, Tembuyser L, Dequeker E, van Krieken JH.

BMC Cancer. 2016 Oct 26;16(1):825.

33.

New developments in the pathology of malignant lymphoma: a review of the literature published from June-August 2016.

van Krieken JH.

J Hematop. 2016 Sep 30;9(3):129-134. eCollection 2016 Sep. Review. No abstract available.

34.

Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma.

Vasaturo A, Di Blasio S, Verweij D, Blokx WA, van Krieken JH, de Vries IJ, Figdor CG.

Histopathology. 2017 Mar;70(4):643-649. doi: 10.1111/his.13070. Epub 2016 Dec 2.

PMID:
27571246
35.

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.

Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li Y, Li J, Medeiros LJ, Young KH.

Leukemia. 2017 Mar;31(3):625-636. doi: 10.1038/leu.2016.243. Epub 2016 Aug 29.

36.

New developments in the pathology of malignant lymphoma. A review of the literature published from January-April 2016.

van Krieken JH.

J Hematop. 2016 Jun 13;9(2):73-83. eCollection 2016 Jun. Review. No abstract available.

37.

How we do: optimizing bone marrow biopsy logistics for sign-out within 2 days.

de Laak-de Vries I, Siebers AG, Burgers L, Diepenbroek C, Link M, Groenen P, van Krieken JH, Hebeda KM.

J Hematop. 2016 Mar 5;9(2):67-71. eCollection 2016 Jun.

38.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

PMID:
27380959
39.

Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.

van den Brand M, Rijntjes J, Hebeda KM, Menting L, Bregitha CV, Stevens WB, van der Velden WJ, Tops BB, van Krieken JH, Groenen PJ.

Histopathology. 2017 Jan;70(2):174-184. doi: 10.1111/his.13015. Epub 2016 Sep 9.

PMID:
27297871
40.

T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines.

Vasaturo A, Halilovic A, Bol KF, Verweij DI, Blokx WA, Punt CJ, Groenen PJ, van Krieken JH, Textor J, de Vries IJ, Figdor CG.

Cancer Res. 2016 Jun 15;76(12):3496-506. doi: 10.1158/0008-5472.CAN-15-3211. Epub 2016 Apr 11.

41.

The Role of Dectin-2 for Host Defense Against Disseminated Candidiasis.

Ifrim DC, Quintin J, Courjol F, Verschueren I, van Krieken JH, Koentgen F, Fradin C, Gow NA, Joosten LA, van der Meer JW, van de Veerdonk F, Netea MG.

J Interferon Cytokine Res. 2016 Apr;36(4):267-76. doi: 10.1089/jir.2015.0040. Epub 2016 Jan 27.

42.

New developments in the pathology of malignant lymphoma. A review of the literature published from September 2015-December 2015.

van Krieken JH.

J Hematop. 2016 Feb 22;9(1):19-27. eCollection 2016 Mar. Review. No abstract available.

43.

A subset of low-grade B cell lymphomas with a follicular growth pattern but without a BCL2 translocation shows features suggestive of nodal marginal zone lymphoma.

van den Brand M, Balagué O, van Cleef PH, Groenen PJ, Hebeda KM, de Jong D, van Krieken JH.

J Hematop. 2015 Sep 2;9(1):3-8. eCollection 2016 Mar.

44.

Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.

Xu-Monette ZY, Deng Q, Manyam GC, Tzankov A, Li L, Xia Y, Wang XX, Zou D, Visco C, Dybkær K, Li J, Zhang L, Liang H, Montes-Moreno S, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Wang SA, Miranda RN, Piris MA, Winter JN, Medeiros LJ, Li Y, Young KH.

Clin Cancer Res. 2016 Jul 15;22(14):3593-605. doi: 10.1158/1078-0432.CCR-15-2296. Epub 2016 Feb 29.

45.

p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.

Xu-Monette ZY, Zhang S, Li X, Manyam GC, Wang XX, Xia Y, Visco C, Tzankov A, Zhang L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Young KH.

Aging (Albany NY). 2016 Feb;8(2):345-65.

46.

Tetraspanin CD37 protects against the development of B cell lymphoma.

de Winde CM, Veenbergen S, Young KH, Xu-Monette ZY, Wang XX, Xia Y, Jabbar KJ, van den Brand M, van der Schaaf A, Elfrink S, van Houdt IS, Gijbels MJ, van de Loo FA, Bennink MB, Hebeda KM, Groenen PJ, van Krieken JH, Figdor CG, van Spriel AB.

J Clin Invest. 2016 Feb;126(2):653-66. doi: 10.1172/JCI81041. Epub 2016 Jan 19.

47.

A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.

Strobbe L, Valke LL, Diets IJ, van den Brand M, Aben K, Raemaekers JM, Hebeda KM, van Krieken JH.

Ann Hematol. 2016 Feb;95(3):417-23. doi: 10.1007/s00277-015-2578-6. Epub 2016 Jan 5.

48.

Partial lack of BCL2 in follicular lymphoma: An unusual immunohistochemical staining pattern explained by ongoing BCL2 mutation.

van den Brand M, Garcia-Garcia M, Mathijssen JJ, Colomo L, Groenen PJ, Serrano S, van Krieken JH.

Pathol Res Pract. 2016 Feb;212(2):148-50. doi: 10.1016/j.prp.2015.12.001. Epub 2015 Dec 9.

PMID:
26725534
49.

RAS testing in metastatic colorectal cancer: advances in Europe.

Van Krieken JH, Rouleau E, Ligtenberg MJ, Normanno N, Patterson SD, Jung A.

Virchows Arch. 2016 Apr;468(4):383-96. doi: 10.1007/s00428-015-1876-7. Epub 2015 Nov 16. Review.

50.

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.

Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH.

Oncotarget. 2016 Jan 19;7(3):2401-16. doi: 10.18632/oncotarget.6262.

Supplemental Content

Loading ...
Support Center